Ascentage Pharma's Olverembatinib Receives FDA and EMA Approval for Phase III Study

Ascentage Pharma Group International has announced that its phase III study of olverembatinib has been cleared by the FDA and EMA. The company is focused on developing novel small therapies for cancers, hepatitis B virus, and age-related diseases through the inhibition of protein-protein interactions to restore apoptosis. Its main products include HQP1351 and apoptosis-targeted drugs APG-1252, APG-2575, and APG-115.